{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:17:47Z","timestamp":1788311867867,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by androgen independence, resistance to chemotherapy, and neuroendocrine features that can emerge de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 AVPC cases using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited shorter overall survival than de novo AVPC (11.8 vs. 26.0 months). Integrative analyses identified regulators of neuronal processes in subsets of cases with neuroendocrine lineage programs, delineating a spectrum of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid\/PDX from a lymph node metastasis that faithfully recapitulates the donor tumor\u2019s molecular and phenotypic features. Genomic profiling identified biallelic inactivation of\n                    <jats:italic>PTEN<\/jats:italic>\n                    ,\n                    <jats:italic>TP53<\/jats:italic>\n                    ,\n                    <jats:italic>RB1<\/jats:italic>\n                    , and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    as potential drivers. These alterations were clonally concordant with circulating tumor DNA from the donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with BCL-2\/BCL-xL and MCL-1 inhibitors. Overall, NCI-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01400-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:56:26Z","timestamp":1775746586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Chennan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JuanJuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana S.","family":"Vargas Solivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Bhadresha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeyra","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanak","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Twohig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri M.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1400_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada, Y. & Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 23, 15 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"1400_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016).","journal-title":"Nat. Med."},{"key":"1400_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I. & Eisenberger, M. A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213\u2013219 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"1400_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"Tzelepi, V. et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin. Cancer Res. 18, 666\u2013677 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1400_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X","volume":"59","author":"B Tetu","year":"1987","unstructured":"Tetu, B. et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study 20 cases. Cancer 59, 1803\u20131809 (1987).","journal-title":"Cancer"},{"key":"1400_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1400_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474\u2013489 e476 (2017).","journal-title":"Cancer Cell"},{"key":"1400_CR8","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang, H. T. et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis\u2014a systematic review and pooled analysis. J. Clin. Oncol. 32, 3383\u20133390 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1400_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca, V. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer 121, 7\u201318 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1400_CR10","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/ERC-21-0140","volume":"28","author":"H Beltran","year":"2021","unstructured":"Beltran, H. & Demichelis, F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr.-Relat. Cancer 28, T67\u2013T78 (2021).","journal-title":"Endocr.-Relat. Cancer"},{"key":"1400_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","volume":"12","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal, R., Zhang, T., Small, E. J. & Armstrong, A. J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J. Natl. Compr. Canc. Netw. 12, 719\u2013726 (2014).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"1400_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).","journal-title":"Nat. Commun."},{"key":"1400_CR13","doi-asserted-by":"publisher","unstructured":"Beshiri, M., Agarwal, S., Yin, J. J. & Kelly, K. Prostate organoids: emerging experimental tools for translational research. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/JCI169616 (2023).","DOI":"10.1172\/JCI169616"},{"key":"1400_CR14","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","volume":"24","author":"ML Beshiri","year":"2018","unstructured":"Beshiri, M. L. et al. A PDX\/Organoid Biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin. Cancer Res. 24, 4332\u20134345 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1400_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pros.24718","volume":"84","author":"J Yin","year":"2024","unstructured":"Yin, J. et al. Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis. Prostate 84, 1033\u20131046 (2024).","journal-title":"Prostate"},{"key":"1400_CR16","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1073\/pnas.112008599","volume":"99","author":"MA Hakimi","year":"2002","unstructured":"Hakimi, M. A. et al. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl. Acad. Sci. USA. 99, 7420\u20137425 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1400_CR17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769 e759 (2018).","journal-title":"Cell"},{"key":"1400_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/stmcls\/sxae025","volume":"42","author":"ML Beshiri","year":"2024","unstructured":"Beshiri, M. L. et al. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer. Stem Cells 42, 526\u2013539 (2024).","journal-title":"Stem Cells"},{"key":"1400_CR19","doi-asserted-by":"publisher","unstructured":"Dang, D. K. & Park, B. H. Circulating tumor DNA: current challenges for clinical utility. J. Clin. Investig. 132, https:\/\/doi.org\/10.1172\/JCI154941 (2022).","DOI":"10.1172\/JCI154941"},{"key":"1400_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608, 199\u2013208 (2022).","journal-title":"Nature"},{"key":"1400_CR21","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","volume":"187","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor. Cell 187, 3409\u20133426 e3424 (2024).","journal-title":"Cell"},{"key":"1400_CR22","doi-asserted-by":"publisher","unstructured":"Garcia-Garcia, L. et al. The transcription factor FEZF1, a direct target of EWSR1-FLI1 in Ewing sarcoma cells, regulates the expression of neural-specific genes. Cancers (Basel) 13, https:\/\/doi.org\/10.3390\/cancers13225668 (2021).","DOI":"10.3390\/cancers13225668"},{"key":"1400_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s42003-019-0506-3","volume":"2","author":"VY Chung","year":"2019","unstructured":"Chung, V. Y. et al. The role of GRHL2 and epigenetic remodeling in epithelial\u2013mesenchymal plasticity in ovarian cancer cells. Commun. Biol. 2, 272 (2019).","journal-title":"Commun. Biol."},{"key":"1400_CR24","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/0008-5472.CAN-14-3602","volume":"75","author":"CL Hsieh","year":"2015","unstructured":"Hsieh, C. L. et al. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 75, 1944\u20131948 (2015).","journal-title":"Cancer Res."},{"key":"1400_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/ng.3648","volume":"48","author":"P Ulz","year":"2016","unstructured":"Ulz, P. et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat. Genet. 48, 1273\u20131278 (2016).","journal-title":"Nat. Genet."},{"key":"1400_CR26","doi-asserted-by":"publisher","first-page":"102953","DOI":"10.1016\/j.isci.2021.102953","volume":"24","author":"K Pozo","year":"2021","unstructured":"Pozo, K. et al. ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. iScience 24, 102953 (2021).","journal-title":"iScience"},{"key":"1400_CR27","doi-asserted-by":"publisher","first-page":"102274","DOI":"10.1016\/j.clgc.2024.102274","volume":"23","author":"R Gagnon","year":"2025","unstructured":"Gagnon, R. et al. Real-world clinical outcomes and prognostic factors in neuroendocrine prostate cancer. Clin. Genitourin. Cancer 23, 102274 (2025).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1400_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"1400_CR29","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA. 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1400_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11\u201322 (2010).","journal-title":"Cancer Cell"},{"key":"1400_CR31","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research, N.","year":"2015","unstructured":"Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"1400_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243 (2012).","journal-title":"Nature"},{"key":"1400_CR33","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J.Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J.Clin."},{"key":"1400_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5534\/wjmh.210070","volume":"40","author":"N Hinata","year":"2022","unstructured":"Hinata, N. & Fujisawa, M. Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview. World J. Mens. Health 40, 217\u2013227 (2022).","journal-title":"World J. Mens. Health"},{"key":"1400_CR35","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMc2000069","volume":"383","author":"BA Mahal","year":"2020","unstructured":"Mahal, B. A. et al. Racial differences in genomic profiling of prostate cancer. N. Engl. J. Med. 383, 1083\u20131085 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1400_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41586-022-05154-6","volume":"609","author":"W Jaratlerdsiri","year":"2022","unstructured":"Jaratlerdsiri, W. et al. African-specific molecular taxonomy of prostate cancer. Nature 609, 552\u2013559 (2022).","journal-title":"Nature"},{"key":"1400_CR37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2767-9764.CRC-22-0245","volume":"2","author":"H Valentine","year":"2022","unstructured":"Valentine, H. et al. Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient. Cancer Res. Commun. 2, 1355\u20131371 (2022).","journal-title":"Cancer Res. Commun."},{"key":"1400_CR38","doi-asserted-by":"publisher","first-page":"101868","DOI":"10.1016\/j.xcrm.2024.101868","volume":"5","author":"IS Senatorov","year":"2024","unstructured":"Senatorov, I. S. et al. Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit. Cell Rep. Med. 5, 101868 (2024).","journal-title":"Cell Rep. Med."},{"key":"1400_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64042-5","volume":"16","author":"JM Jim\u00e9nez-Vacas","year":"2025","unstructured":"Jim\u00e9nez-Vacas, J. M. et al. Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer. Nat. Commun. 16, 8806 (2025).","journal-title":"Nat. Commun."},{"key":"1400_CR40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2767-9764.CRC-22-0427","volume":"3","author":"T Mitra Ghosh","year":"2023","unstructured":"Mitra Ghosh, T. et al. Metronomic administration of topotecan alone and in combination with docetaxel inhibits epithelial-mesenchymal transition in aggressive variant prostate cancers. Cancer Res. Commun. 3, 1286\u20131311 (2023).","journal-title":"Cancer Res. Commun."},{"key":"1400_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00176","volume":"3","author":"ST Hennigan","year":"2019","unstructured":"Hennigan, S. T. et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis. Oncol. 3, 1\u201313 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1400_CR42","doi-asserted-by":"publisher","first-page":"17087","DOI":"10.1073\/pnas.1108745108","volume":"108","author":"A Kumar","year":"2011","unstructured":"Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA. 108, 17087\u201317092 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1400_CR43","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","volume":"84","author":"R Shrestha","year":"2024","unstructured":"Shrestha, R. et al. An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression. Cancer Res. 84, 3086\u20133100 (2024).","journal-title":"Cancer Res."},{"key":"1400_CR44","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/pros.23437","volume":"77","author":"L Woods-Burnham","year":"2017","unstructured":"Woods-Burnham, L. et al. The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: implications for prostate cancer health disparities research using pre-clinical models. Prostate 77, 1601\u20131608 (2017).","journal-title":"Prostate"},{"key":"1400_CR45","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1101\/gr.180281.114","volume":"24","author":"G Ha","year":"2014","unstructured":"Ha, G. et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 24, 1881\u20131893 (2014).","journal-title":"Genome Res."},{"key":"1400_CR46","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.xgen.2022.100112","volume":"2","author":"C Shale","year":"2022","unstructured":"Shale, C. et al. Unscrambling cancer genomes via integrated analysis of structural variation and copy number. Cell Genom. 2, 100112 (2022).","journal-title":"Cell Genom."},{"key":"1400_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35076-w","volume":"13","author":"AL Doebley","year":"2022","unstructured":"Doebley, A. L. et al. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat. Commun. 13, 7475 (2022).","journal-title":"Nat. Commun."},{"key":"1400_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s43018-023-00533-y","volume":"4","author":"I Leshchiner","year":"2023","unstructured":"Leshchiner, I. et al. Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat. Cancer 4, 550\u2013563 (2023).","journal-title":"Nat. Cancer"},{"key":"1400_CR49","doi-asserted-by":"publisher","first-page":"D100","DOI":"10.1093\/nar\/gky1128","volume":"47","author":"I Yevshin","year":"2019","unstructured":"Yevshin, I., Sharipov, R., Kolmykov, S., Kondrakhin, Y. & Kolpakov, F. GTRD: a database on gene transcription regulation-2019 update. Nucleic Acids Res. 47, D100\u2013D105 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1400_CR50","doi-asserted-by":"publisher","unstructured":"Agarwal, S. et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody\u2013drug conjugate treatment in metastatic prostate cancer models. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/JCI162148 (2023).","DOI":"10.1172\/JCI162148"},{"key":"1400_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"1400_CR52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Cell"},{"key":"1400_CR53","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jbm.a.32238","volume":"91","author":"CA Wu","year":"2009","unstructured":"Wu, C. A. et al. Responses in vivo to purified poly(3-hydroxybutyrate-co-3-hydroxyvalerate) implanted in a murine tibial defect model. J. Biomed. Mater. Res. A 91, 845\u2013854 (2009).","journal-title":"J. Biomed. Mater. Res. A"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01400-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:02:46Z","timestamp":1780963366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01400-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}